Search
-
Old age begins at 66, but six in ten say they are not looking forward to it
New research across 32 countries dives into global attitudes to ageing, with 57% on average saying they are not looking forward to old age.
-
The Experience Perspective
The Experience Perspective is an Ipsos podcast and LinkedIn Live series covering everything from Customer and Employee Experience to Channel Performance.
-
Transforming the Swiss TELCO Landscape: From Basic Connections to Emotional Engagement
In an increasingly competitive Swiss TELCO market, standing out is crucial. Discover how brands can differentiate through innovative technologies, emotional connections, and empathy-driven engagement to capture consumer loyalty.
-
After Trump’s tariff threats, Europeans rally for economic resilience
Recent data from Ipsos’ EuroPulse reveals a European public that are deeply concerned about Europe's ability to defend its economic interests on the world stage.
-
America’s reputation drops across the world
The proportion saying the United States will have a positive influence on world affairs has fallen in 26 out of 29 countries over the last six months. America’s reputation has fallen most markedly in Canada. For the first time in our decade-long survey series, China is placed ahead of the US when it comes to playing a positive role on the international scene.
-
Exclusive IPSOS Event on “Synthetic data and predictive AI: beyond the hype” at Lausanne
Contact us to join our Exclusive webinar on Synthetic data and predictive AI: beyond the hype
-
Ipsos Update – January 2025
Almanac, Predictions, Democracy … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
-
Positivity about how this year has gone highest since before the pandemic
The Ipsos Predictions Survey 2025 is a 33-country study which looks at people’s expectations and predictions for the year ahead.
-
Predicting Opportunity in Emerging Therapies
The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.